PMID: 16522275Mar 9, 2006Paper

The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease

Current Diabetes Reports
Kambiz Kalantarinia, Mark D Okusa

Abstract

Diabetic nephropathy, the most common cause of end-stage renal disease in the United States, is also associated with increased cardiovascular mortality. The renin-angiotensin-aldosterone system (RAAS) plays a central role in the development and progression of kidney disease and cardiovascular disease. Randomized, controlled trials have demonstrated renoprotection with the use of angiotensin receptor blockers (ARBs) in type 2 and angiotensin-converting enzyme inhibitors (ACEIs) in type 1 diabetes. More recent studies have demonstrated similar cardiovascular benefits with the use of ARBs compared with ACEIs. The combination of the two classes of RAAS blockers has been investigated in large studies of patients with heart failure and after myocardial infarction, and a few small studies of patients with diabetic nephropathy. In this review, we summarized the results of the studies on the benefits of ARBs, ACEIs, and their combination in patients with diabetic nephropathy or cardiovascular diseases.

References

Apr 1, 1992·Kidney International·E M DamsgaardC E Mogensen
Mar 1, 1994·Current Opinion in Nephrology and Hypertension·A J Naftilan
Apr 26, 1993·Archives of Internal Medicine·V J Dzau
Dec 1, 1995·European Heart Journal·A D Struthers
Dec 18, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C A JonesL Y Agodoa
Nov 16, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·K R TuttleR Short
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Mar 31, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A V KshirsagarR E Colindres
Sep 21, 2000·Kidney International. Supplement·D J LeeheyR Singh
Feb 24, 2001·Current Opinion in Nephrology and Hypertension·H M Siragy, R M Carey
May 4, 2001·The American Journal of Cardiology·D WeissW R Taylor
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
May 11, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Chih-Chang WeiLouis J Dell'Italia
May 29, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Peter JacobsenHans-Henrik Parving
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Aug 7, 2002·The Journal of Clinical Investigation·Joost P SchanstraJean-Loup Bascands
Sep 13, 2002·Journal of the American College of Cardiology·Maylene WongUNKNOWN Val-HeFT Heart Failure Trial Investigators
Mar 28, 2003·Journal of the American Society of Nephrology : JASN·Peter JacobsenHans-Henrik Parving
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee

❮ Previous
Next ❯

Citations

Jan 22, 2010·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·R H MohamedT A Abd El-Aziz
Jul 14, 2007·Heart & Lung : the Journal of Critical Care·Jack P Chen
Mar 23, 2011·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Ravi P RaoBp Srinivasan
Aug 10, 2007·American Journal of Physiology. Renal Physiology·Swasti TiwariCarolyn A Ecelbarger
Aug 10, 2020·Advances in Therapy·Claudio Borghi, Stefano Omboni

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.